Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2459 • ACR Convergence 2025
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Milena Delai¹, Rachel Simon¹, Eduardo Mantovani Cardoso² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
Abstract Number: 2442 • ACR Convergence 2025
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Danae-Mona Nöthling¹, Kirill Anoshkin¹, Panagiotis Garantziotis¹, Laura Bucci¹, Tobias Rothe², Jule Taubmann³, Futoshi Iwata¹, Melanie Hagen¹, Andreas Wirsching¹, Simon Völkl⁴, Fabian Müller⁵, Aline Bozec¹, Andreas Mackensen⁶, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital of Erlangen, Erlangen, Germany, ⁶Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by aberrant B cell activation and autoantibody production. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy induces a short,…
Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Michaela Harter¹, Rebecca Hetrick², James Slaven³ and Martha Rodriguez⁴, ¹Indiana University School of Medicine, Indianapolis, IN, ²Indiana University School of Medicine, Zionsville, IN, ³Indiana University School of Medicine, Indianapolis, ⁴Riley Hospital For Children At Indiana University, Carmel, IN
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
Abstract Number: 2407 • ACR Convergence 2025
Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Jorge Juan Fragío Gil¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Isabel Martínez Cordellat⁴, Juan José Lerma Garrido⁴ and Cristina Campos Fernández⁵, ¹Hospital General Universitario, Valencia, Spain, ²Hospital General de Valencia, Valencia, Spain, ³Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia
Background/Purpose: One common and clinically important form of systemic lupus erythematosus (SLE) is neuropsychiatric systemic lupus erythematosus (NPSLE). This systematic review and meta-analysis aimed to…
Abstract Number: 2388 • ACR Convergence 2025
Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
Carmen Lasa Teja¹, Carmen Bejerano-Herreria², Laura Muñoz-Llopis², Pilar Ortiz-Lavin², Carolina Aguirre-Portilla², Virginia Portilla González³ and Ricardo Blanco⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents a highly heterogeneous clinical course and prognosis. In line with EULAR recommendations and treat-to-target (T2T) strategies, comprehensive assessment of…
Abstract Number: 2222 • ACR Convergence 2025
Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Reem Farhat¹, Lawrence Rudski², Natalie Dayan³, Catherine Henin⁴, Daniela Villegas Martinez⁴, Sariya Sahussarungsi¹, Pasinee Kanaprach¹, Sasha Bernatsky⁵, Gabriel Altit⁴ and Evelyne Vinet⁵, ¹McGill University, Faculty of Medicine and Health Sciences, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Montreal Children's Hospital, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) increases the risk of placenta-mediated adverse pregnancy outcomes (APO) and may impact offspring cardiovascular health. Transplacental maternal anti-Ro antibodies can…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 1892 • ACR Convergence 2025
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
siddharth Agrawal¹, Freya Shah¹, Ritu Tated², Radhe Shah³ and Mahir Modi⁴, ¹landmark medical center, cumberland, RI, ²New York Medical College, Vallaha, ³Beth Israel Deaconess Medical Center, Boston, ⁴GCS Medical College, hospital and Research Centre, Ahmedabad, India
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention…
Abstract Number: 1840 • ACR Convergence 2025
Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
Lorenzo Beretta¹, Martina Iacubino², Lorenzo Rocco³, Alexandre Voskuijl⁴, Marta Alarcon-Riquelme⁵, Guillermo Barturen⁶, LIam Grimmett⁷, Matt Kerr⁷, Chiara Bellocchi³, Barbara Vigone⁸, Alessandro Santaniello⁸ and Ioannis Parodis⁹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²UNIMI, Milano, Milan, Italy, ³University of Milan, Milan, Italy, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁷Owlstone Medical, Cambridge, United Kingdom, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: 3TR (taxonomy, treatment, targets and remission) aims to provide insights into the mechanisms of response and non-response to treatment in systemic autoimmune diseases, including…
Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abhimanyu Amarnani¹, Cristobal F. Rivera², Susan RS Gottesman³, Zakia Azad¹, Mingyang Yi⁴, Joshua Prasad⁴, Cynthia Loomis⁴, Andy Lee⁴, Nimat Ullah⁴, Bhama Ramkhelawon⁵ and Gregg J. Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University Grossman Department of Surgery, New York, ³SUNY Downstate Health Sciences University, New York, ⁴New York University Grossman School of Medicine, New York, ⁵New York University Department of Surgery, New York
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…
Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Vitor Aguiar¹, Marcella Franco¹, Nada Abdel Aziz¹, Daniela Fernandez-Salinas², Marcos Chinas¹, Mariasilvia Colantuoni², Qian Xiao¹, Nicolaj Hackert¹, Yifei Liao³, Rodrigo Cervantes-Diaz¹, Marc Todd¹, Brian Wauford¹, Alex Wactor¹, Vaishali Prahalad¹, Raquel Laza-Briviesca¹, Roxane Darbousset¹, Qiang Wang¹, Scott Jenks⁴, Kevin Cashman⁴, Esther Zumaquero⁴, Zhu Zhu¹, Junning Case³, Paloma Cejas⁵, Miguel Munoz-Gomez⁵, Hannah Ainsworth⁶, Miranda Marion⁷, Mehdi Benamar¹, Pui Lee⁸, Lauren Henderson⁹, Margaret Chang², Kevin Wei¹⁰, Henry Long⁵, Carl Langefeld¹¹, Benjamin Gewurz³, Ignacio Sanz⁴, Jeffrey Sparks¹², Esra Meidan¹³, Peter Nigrovic² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Boston, ²Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Emory University, Atlanta, ⁵Dana Farber Cancer Institute, Boston, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest, Winston-Salem, ⁸Boston Children's Hospital, Newton, MA, ⁹Boston Children's Hospital, Watertown, MA, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Wake Forest University School of Medicine, Winston Salem, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Boston Children's Hospital, Somerville, MA
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 1513 • ACR Convergence 2025
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Ufuoma Mamoh¹, Queeneth Edwards², Chukwuemelie Okeke³, Justin Riley Lam⁴, Soziema Salia⁵ and Christhopher Haas⁶, ¹Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ²Georgia Southern University, Statesboro, GA, ³Maimonides Medical Center, Brooklyn, NY, ⁴Albert Einstein Medical Center, Philadelphia, PA, ⁵MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ⁶MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that disproportionately affects racial and ethnic minority populations, particularly Black/African American and Hispanic/Latino individuals. In…
Abstract Number: 1490 • ACR Convergence 2025
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
judith hernández-Sánchez¹, Beatriz Tejera Segura², Luis Bausá Gimeno¹, Doryan García Olivas¹, Patricia González Terrats¹, MA Acosta Mérida¹, Diana Botello Corzo¹, Daniel Batista perdomo¹, Sergio Machin González¹, F Javier Nóvoa Medina¹ and Jose Angel Hernandez³, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ²Hospital Insular de Gran Canaria, Las palmas, Spain, ³Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].